Zacks.com on MSN10h
VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares UpThe FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.
The following is a summary of “Feasibility of trancutaneous auricular vagus nerve stimulation in Black and Hispanic/Latino people with peripheral neuropathy,” published in the January 2025 issue of ...
GlobalData on MSN16h
FDA approves Vertex’s acute pain treatment JournavxThe US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
In recent weeks, reports have been circulating about severe reactions in people who've taken over-the-counter vitamin B6 supplements.
The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...
Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...
People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it can be difficult to ...
The drug, suzetrigine, made by Boston-based Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside ...
Analysts at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO – Get Free Report) in a research report issued on Friday. The firm set a “sell” rating on the medical device company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback